qanastek/EMEA-V3 huggingface dataset:
104 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
Huwa essenzjali li jinżamm kontroll tajjeb tal- pazjenti kkurati bl- insulina (dawk li jiddependu fuq l - insulina jew id- dijabete ta 'waqt it- tqala) matul it- tqala.
Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently.
112 Il- korrezzjoni ta 'zokkor baxx fid- demm moderatament severa tista' tinkiseb b' għoti tal- glucagon intramuskolari jew taħt il- ġilda, segwita minn karboidrat orali meta l- pazjent jirkupra biżżejjed.
105 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
It- teħid sostenut ta 'karboidrati u l- osservazzjoni jistgħu jkunu neċessarji minħabba li zokkor baxx fid - demm jista' jerġa jseħħ wara li l- pazjent ikun jidher li rkupra klinikament.
Studies also demonstrate that the dissociation of binding to the insulin receptor of insulin lispro is equivalent to human insulin.
113 lispro mar- riċetturi ta 'l- insulina, hija ekwivalenti ma' l- insulina umana.
Protamine sulphate m-cresol [1.76 mg/ ml] Phenol [0.80 mg/ ml] 106 Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.
Protamine sulphate m- cresol [1. 76 mg/ ml] Phenol [0. 80 mg/ ml] Glycerol Dibasic sodium phosphate. 7H2O Zinc oxide Ilma għall- injezzjonijiet Hydrochloric acid u sodium hydroxide jistgħu jintużaw biex jaġġustaw il- pH għal 7. 0 - 7. 8.
5 x 3 ml Humalog BASAL 100 U/ ml KwikPens 2 x (5 x 3 ml) Humalog BASAL 100 U/ ml KwikPens
5 x 3ml Humalog BASAL 100 U/ ml KwikPens 2 x (5 x 3 ml) Pinen Humalog BASAL 100 U/ ml KwikPens
Instructions for use and handling The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Il- KwikPen għandha tkun imdawra fil- pali ta 'l- idejn għaxar darbiet u maqlubin 180o għaxar darbiet immedjatamnet qabel ma jintużaw sabiex tirrisospendi l- insulina sakemm tidher imċajpra jew qiesa
5 x 3 ml Humalog BASAL 100 U/ ml KwikPen 2 x (5 x 3 ml) Humalog BASAL 100 U/ ml KwikPen
5 x 3ml Humalog BASAL 100 U/ ml KwikPen 2 x (5 x 3 ml) Humalog BASAL 100 U/ ml KwikPen
108 ANNEX II
115 ANNESS II
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
MANIFATTURI TAS- SUSTANZA BIJOLOĠIKA ATTIVA U DETENTURI TA ’ L- AWTORIZZAZZJONI TAL - MANIFATTURA RESPONSABBLI GĦALL- HRUĠ TAL - LOTT
109 A MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
MANIFATTURI TAS- SUSTANZA BIJOLOĠIKA ATTIVA U DETENTURI TA ’ L - AWTORIZZAZZJONI TAL- MANIFATTURA RESPONSABBLI GĦALL- HRUĠ TAL - LOTT
Names and addresses of the manufacturers of the biological active substance
Ismijiet u indirizzi tal- manifatturi tas- sustanza bijoloġika attiva
Fermentation:
Fermentazzjoni:
Names and addresses of the manufacturers responsible for batch release
Ismijiet u indirizzi tal- manifatturi responsabbli għall- ħruġ tal- lott
Vials
Kunjetti
Lilly France S. A. S., Rue du Colonel Lilly, 67640 Fegersheim, France.
Lilly France S. A. S., Rue du Colonel Lilly, 67640 Fegersheim, Franza.
KG, Teichweg 3, 35396 Giessen, Germany.
KG, Teichweg 3, 35396 Giessen, Ġermanja.
Cartridges and disposable pens called the „ Pen“
Skrataċ u pinen li jintremew wara l- użu li jissejħu “ Pinna ”
Cartridges and disposable pens called the „ Pen“ besides Humalog BASAL presentations Eli Lilly Italia S. p. A., Via A.
Skrataċ u pinen li jintremew wara l- użu li jissejħu “ Pinna ” ħlief għal presentazzjonijiet ta ’ Humalog BASAL Eli Lilly Italia S. p. A., Via A.
Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.
Gramsci 731- 733, 50019 Sesto Fiorentino, Firenze, L- Italja.
Disposable pens called the „ KwikPen“
Pinen li jintremew wara l- użu li jissejħu “ KwikPen ”
KG, Teichweg 3, 35396 Giessen, Germany.
KG, Teichweg 3, 35396 Giessen, Il- Ġermanja.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch
Fuq il- fuljett ta 'tagħrif tal- prodott mediċinali għandu jkun hemm l- isem u l- indirizz tal- manifattur responsabbli għall- ħruġ tal- lott konċernat
110 ANNEX III
117 ANNESS III
112 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
119 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (1 VIAL)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (1 KUNJETT)
Humalog 100 U/ ml solution for injection in vial Insulin lispro (rDNA origin)
Humalog 100 U/ ml soluzzjoni għall- injezzjoni ġo kunjett Insulina lispro (oriġini rDNA)
Insulin lispro (rDNA origin) 100 U/ ml (3.5 mg/ ml)
Insulina lispro (oriġini rDNA) 100 U/ ml (3. 5 mg/ ml)
Contains glycerol, zinc oxide, dibasic sodium phosphate 7H20 with m-cresol as a preservative in water for injection.
Għandu glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol bħala preservattiv fl- ilma għall- injezzjonijiet.
Sodium hydroxide and/ or hydrochloric acid may have been used to adjust acidity.
Sodium hydroxide u/ jew hydrochloric acid jistgħu kienu użati biex tkun aġġustata l- aċidità.
Solution for injection, 1 x 10 ml vial
Soluzzjoni għall- injezzjonijiet, 1 X 10 ml kunjett
Subcutaneous and intravenous use
Għall- użu taħt il- ġilda u ġol- vina
OTHER SPECIAL WARNING, IF NECESSARY
TWISSIJA SPEĊJALI OĦRA, JEKK MEĦTIEĠA
READ ENCLOSED PACKAGE LEAFLET
AQRA L- FULJETT TA ’ TAGĦRIF ĠOL- PAKKETT
Do not freeze.
Aħżen fi friġġ (2°C - 8°C) Tagħmlux fil- friża.
Do not expose to excessive heat or direct sunlight.
Tpoġġix fi sħana eċċessiva jew direttament fix- xemx.
Once in use, vials may be used for up to 28 days.
120 La darba jkunu fl- użu, il- kunjetti jistgħu jintużaw sa 28 ġurnata.
Vials in use should be stored below 30°C.
Kunjetti li qed jintużaw għandhom ikunu maħżuna f’ temperatura taħt 30°C.
114 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
121 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT( 2 VIALS)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 FJAL1)
Solution for injection, 2 x 10 ml vials
Soluzzjoni għall- injezzjonijiet, 2 X 10 ml kunjetti
Once in use, vials may be used for up to 28 days.
122 La darba jkunu fl- użu, il- kunjetti jistgħu jintużaw sa 28 ġurnata.
116 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
123 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (5 X 1 VIAL)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (5 X 1 FJAL1)
Solution for injection, Part of a multi-pack of 5 x (1 x 10 ml) vials.
Soluzzjoni għall- injezzjonijiet, Parti minn pakkett multiplu ta ’ 5 X (1 X 10 ml) kunjetti.
Do not sell separately.
Tbigħhomx separatament.
Once in use, vials may be used for up to 28 days.
124 La darba jkunu fl- użu, il- kunjetti jistgħu jintużaw sa 28 ġurnata.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
ISEM U INDIRIZZ TA ’ TAD- DETENTUR TA ’ L- AWTORIZZAZZJONI GĦAT - TQEGĦID FIS- SUQ
118 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
125 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
LABEL TEXT
KITBA TA ’ FUQ IT- TIKKETTA
NAME OF THE MEDICINAL PRODUCT AND ROUTES OF ADMINISTRATION
ISEM TAL- PRODOTT MEDIĊINALI U MNEJN GĦANDU JINGĦATA
Humalog 100 U/ ml solution for injection in vial Insulin lispro Subcutaneous and intravenous use
Humalog 100 U/ ml soluzzjoni għall- injezzjoni ġo kunjett Insulina lispro Għall- użu taħt il- ġilda u ġol- vina
119 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
126 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (5 x 3ml cartridges)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (5 X 3 ml skrataċ)
Humalog 100 U/ ml solution for injection in cartridge Insulin lispro (rDNA origin)
Humalog 100 U/ ml soluzzjoni għall- injezzjoni fi skartoċċ Insulina lispro (oriġini rDNA)
Contains glycerol, zinc oxide, dibasic sodium phosphate7H20 with m-cresol as a preservative in water for injection.
Għandu glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol bħala preservattiv fl- ilma għall- injezzjonijiet.
Solution for injection, 5 x 3ml cartridges
Soluzzjoni għall- injezzjonijiet, 5 X3 ml skrataċ
OTHER SPECIAL WARNINGS, IF NECESSARY
TWISSIJA SPEĊJALI OĦRA, JEKK MEĦTIEĠA
These cartridges are for use with a 3 ml pen only.
Dawn l- iskrataċ għandhom jintużaw biss ma’ pinen ta ’ 3 ml.
If the 40 U/ ml vial is the product normally prescribed, do not take insulin from a 100 U/ ml cartridge using a 40 U/ ml syringe.
Jekk il- kunjett ta ’ 40 U/ ml hu l- prodott normalment li tieħu skond ir- riċetta tat- tabib, tiħux insulina minn skartoċċ ta ’ 100 U/ ml billi tuża siringa ta ’ 40 U/ ml.
Once in use cartridges may be used for up to 28 days.
La darba jkunu fl- użu, l- iskrataċ jistgħu jintużaw sa 28 ġurnata.
Following insertion in a pen, the cartridge and pen should be stored below 30°C and should not be refrigerated.
Wara li ddaħħal l- iskartoċċ ġol- pinna, l- iskartoċċ u l- pinna għandom jinħażnu f’ temperatura taħt 30°C u m’ għandhomx jitpoġġew fil- friġġ.
To open, lift here and pull CARTON HAS BEEN OPENED
IL- KARTUNA NFETĦET.
121 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
128 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA JEW, U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml cartridges)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 X 5 X 3 ml skrataċ)
Solution for injection Part of a multi-pack of 2 x (5 x 3ml) cartridges.
Soluzzjoni għall- injezzjonijiet, Parti minn pakkett multiplu ta ’ 2 X (5 X3 ml) skrataċ.
123 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
130 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog 100 U/ ml solution for injection in cartridge Insulin lispro Subcutaneous and intravenous use
Humalog 100 U/ ml soluzzjoni għall- injezzjoni fi skartoċċ Insulina lispro Għall- użu taħt il- ġilda u ġol- vina
124 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
131 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT
KLIEM FUQ IL- KARTUNA TA ’ BARRA
Humalog Mix25 100 U/ ml suspension for injection in vial 25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Humalog Mix25 100 U/ ml soluzzjoni għall- injezzjoni fi kunjett 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA)
25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin) 100 U/ ml (3.5 mg/ ml)
25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA) 100 U/ ml (3. 5 mg/ ml)
Contains protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate.7H2O with m-cresol and phenol as preservatives in water for injections.
Għandu glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol bħala preservattiv fl- ilma għall- injezzjonijiet.
Suspension for injection 1 X 10 ml vial
Suspensjoi għall- injezzjoni, 1 X 10 ml kunjett
Subcutaneous use
Għall- użu taħt il- ġilda
Resuspend carefully.
Irrisospendi bir- reqqa.
See enclosed package leaflet.
Ara l- fuljett ta ’ tagħrif ġol- pakkett.
Once in use, vials may be used for up to 28 days.
La darba jkunu fl- użu, il- kunjetti jistgħu jintużaw sa 28 ġurnata.
Vials in use should be stored below 30°C.
Kunjetti li qed jintużaw għandom jinħażnu f’ temperatura taħt 30°C.
126 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
133 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix25 100 U/ ml suspension for injection in vial 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Humalog Mix25 100 U/ ml soluzzjoni għall- injezzjoni fi kunjett 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA) Għall- użu taħt il- ġilda
127 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
134 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (5 x 3ml cartridges)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (5 X 3ml skrataċ)
Humalog Mix25 100 U/ ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Humalog Mix25 100 U/ ml suspensjoni għall- injezzjoni fi skartoċċ 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA)
Contains protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7 H20 with m-cresol and phenol as preservatives in water for injections.
Għandu glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol bħala preservattiv fl- ilma għall- injezzjonijiet.
Suspension for injection 5 x 3ml cartridges
Suspensjoi għall- injezzjoni, 5 X 3ml skrataċ
OTHER SPECIAL WARNING, IF NECESSARY
TWISSIJA( IET) SPEĊJALI OĦRA, JEKK MEĦTIEĠA
These cartridges are for use with a 3 ml pen only.
Dawn l- iskrataċ huma għall- użu ma ’ pinen ta ’ 3ml biss.
Following insertion in a pen, the cartridge and pen should be stored below 30°C and should not be refrigerated.
Wara li ddaħħal l- iskartoċċ fil- pinna, l- iskartoċċ u l- pinna għandom jinħażnu f’ temperatura taħt 30°C u m’ għandhomx ikunu ġol- friġġ.
129 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
136 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml cartridges)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 X 5 X 3ml skrataċ)
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) cartridges.
Suspensjoi għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 X (5 X 3ml) skrataċ.
131 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
138 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix25 100 U/ ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Humalog Mix25 100 U/ ml soluzzjoni għall- injezzjoni fi skartoċċ 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA) Għall- użu taħt il- ġilda
132 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
139 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix50 100 U/ ml suspension for injection in vial 50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
Humalog Mix50 100 U/ ml suspensjoni għall- injezzjoni f’ kunjett 50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA)
50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin) 100 U/ ml (3.5 mg/ ml)
50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA) 100 U/ ml (3. 5 mg/ ml)
Contains protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate.7H2O with m-cresol and phenol as preservatives in water for injections.
Għandu protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol u phenol bħala preservattivi fl- ilma għall- injezzjonijiet.
134 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
141 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix50 100 U/ ml suspension for injection in vial 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Humalog Mix50 100 U/ ml soluzzjoni għall- injezzjoni f’ kunjett 50% insulina lispro and 50% insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
135 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
142 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix50 100 U/ ml suspension for injection in cartridge 50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
Humalog Mix50 100 U/ ml suspensjoni għall- injezzjoni fi skartoċċ 50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA)
137 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
144 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Contains protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7 H20 with m-cresol and phenol as preservatives in water for injections.
Għandu protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol u phenol bħala preservattivi fl- ilma għall- injezzjonijiet.
10.
145 10.
139 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
146 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix50 100 U/ ml suspension for injection in cartridge 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Humalog Mix50 100 U/ ml suspensjoni għall- injezzjoni fi skartoċċ 50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA) Għall- użu taħt il- ġilda
140 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
147 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog BASAL 100 U/ ml suspension for injection in cartridge Insulin lispro protamine suspension (rDNA origin)
Humalog BASAL 100 U/ ml suspensjoni għall- injezzjoni fi skartoċċ Insulina lispro protamine suspensjoni (oriġini rDNA)
Insulin lispro protamine suspension (rDNA origin) 100 U/ ml (3.5 mg/ ml)
Insulina lispro protamine suspensjoni (oriġini rDNA) 100 U/ ml (3. 5 mg/ ml)
5 X 3ml cartridges
Suspensjoi għall- injezzjoni, 5 X 3ml skrataċ
Once in use cartridges may be used for up to 21 days.
La darba jkunu fl- użu, l- iskrataċ jistgħu jintużaw sa 21 ġurnata.
142 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
149 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml cartridges)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 x 5 x 3ml skrataċ)
Part of a multi-pack of 2 x (5 x 3ml) cartridges.
Suspensjoi għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 x (5 x 3ml) skrataċ.
Do not sell separately.
Ma jinbigħux separatament.
144 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
151 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog BASAL 100 U/ ml suspension for injection in cartridge Insulin lispro protamine suspension Subcutaneous use
Humalog BASAL 100 U/ ml suspensjoni għall- injezzjoni fi skartoċċ Suspensjoni ta ’ insulin lispro protamine Għall- użu taħt il- ġilda
145 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
152 153 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (5 x 3ml Pens)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (5 X 3ml Pinnen)
Humalog Pen 100 U/ ml solution for injection Insulin lispro (rDNA origin)
Pinna Humalog 100 U/ ml soluzzjoni għall- injezzjoni Insulina lispro (oriġini rDNA)
Insulin lispro (rDNA origin) 100 U/ ml (3.5 mg/ ml)
Insulina lispro protamine suspensjoni (oriġini rDNA) 100 U/ ml (3. 5 mg/ ml)
Contains glycerol, zinc oxide, dibasic sodium phosphate 7 H20 with m-cresol as a preservative in water for injections.
Għandu glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol bħala preservattiv fl- ilma għall- injezzjonijiet.
Solution for injection 5 x 3ml Pens
Soluzzjoni għall- injezzjoni, 5 X 3ml Pinnen
READ ENCLOSED PACKAGE LEAFLET
AQRA L- FULJETT TA ’ TAGĦRIF ĠOL- PAKKETT,
Once in use pens may be used for up to 28 days.
La darba jkunu fl- użu, il- pinnen jistgħu jintużaw sa 28 ġurnata.
Pens in use should be stored below 30°C and should not be refrigerated.
Pinnen li qed jintużaw għandom jinħażnu f’ temperatura taħt 30°C u m’ għandhomx ikunu ġol- friġġ.
If seal is broken before first use, contact pharmacist.
Jekk is- siġill ikun miftuħ qabel l- ewwel użu, ikkuntattja lill- ispiżjar.
Follow priming instructions.
Segwi l- istruzzjonijiet ta ’ l- ipprajmar
147 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
155 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml Pens)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 X 5 X 3ml Pinnen)
Solution for injection Part of a multi-pack of 2 x (5 x 3ml) Pens.
Soluzzjoni għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 X (5 X 3ml) Pinnen.
149 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
157 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Pen 100 U/ ml solution for injection Insulin lispro Subcutaneous and intravenous use
Pinna Humalog 100 U/ ml soluzzjoni għall- injezzjoni Insulina lispro Għall- użu taħt il- ġilda u ġol- vina
150 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
158 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix25 100 U/ ml Pen suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Pinna Humalog Mix25 100 U/ ml suspensjoni għall- injezzjoni 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA)
Contains protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7 H20 with m-cresol and phenol as preservatives in water for injections.
Għandu protamine sulphate, glycerol, zinc oxide, dibasic sodium phosphate 7H20 ma ’ m- cresol u phenol bħala preservattiv fl- ilma għall- injezzjonijiet.
Suspension for injection 5 x 3ml Pens
Suspensjoni għall- injezzjoni, 5 X 3ml Pinnen.
Resuspend carefully.
Irrissospendi bir- reqqa.
152 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
160 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) Pens.
Suspensjoni għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 X (5 X 3ml) Pinnen.
READ ENCLOSED PACKAGE LEAFLET
AQRA L- FULJETT TA ’ TAGĦRIF ĠOL- PAKKETT Irrissospendi bir- reqqa.
10.
161 10.
154 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
162 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix25 100 U/ ml Pen suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Pinna Humalog Mix25 100 U/ ml suspensjoni għall- injezzjoni 25% insulina lispro and 75% insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
155 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
163 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix50 100 U/ ml Pen suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
Pinna Humalog Mix50 100 U/ ml suspensjoni għall- injezzjoni 50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA)
157 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
165 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
159 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
167 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix50 100 U/ ml Pen suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Pinna Humalog Mix50 100 U/ ml suspensjoni għall- injezzjoni 50% insulina lispro and 50% insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
160 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
168 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog BASAL 100 U/ ml Pen suspension for injection Insulin lispro protamine suspension (rDNA origin)
Pinna Humalog BASAL 100 U/ ml suspensjoni għall- injezzjoni Insulina lispro protamine suspensjoni (oriġini rDNA)
Suspension for injection 5 X 3ml Pens
Suspensjoni għall- injezzjoni, 5 X 3ml Pinnen.
Once in use pens may be used for up to 21 days.
La darba jkunu fl- użu, il- pinnen jistgħu jintużaw sa 21 ġurnata.
162 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
170 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml Pens)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 x 5 x 3ml Pinen)
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) Pens.
Suspensjoni għall- injezzjoni, Parti minn pakkett multiplu 2 x (5 x 3ml) Pinen.
Do not sell separately.
Ma jinbigħux separatament
164 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
172 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog BASAL 100 U/ ml Pen suspension for injection Insulin lispro protamine suspension Subcutaneous use
Pinna Humalog BASAL 100 U/ ml suspensjoni għall- injezzjoni Insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
165 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
173 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog 100 U/ ml KwikPen, solution for injection Insulin lispro (rDNA origin)
Humalog 100 U/ ml KwikPen, soluzzjoni għall- injezzjoni Insulina lispro (oriġini rDNA)
Solution for injection 5 x 3ml pre-filled pens
Soluzzjoni għall- injezzjoni, 5 x 3ml pinen mimlijin għal- lest
167 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
175 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
OUTER CARTON TEXT (2 x 5 x 3ml Pens)
KLIEM FUQ IL- KARTUNA TA ’ BARRA (2 X 5 X 3ml Pinen)
Solution for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Soluzzjoni għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 x (5 x 3ml) pinen mimlijin għal- lest.
169 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
177 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog 100 U/ ml KwikPen, solution for injection Insulin lispro Subcutaneous and intravenous use
Humalog 100 U/ ml KwikPen, soluzzjoni għall- injezzjoni Insulina lispro Għall- użu taħt il- ġilda u ġol- vina
170 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
178 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix25 100 U/ ml KwikPen, suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Humalog Mix25 100 U/ ml KwikPen, suspensjoni għall- injezzjoni 25% insulina lispro and 75% insulina lispro protamine suspensjoni (oriġini rDNA)
Suspension for injection 5 x 3ml pre-filled pens
Suspensjoni għall- injezzjoni, 5 x 3ml pinen mimlijin għal- lest.
172 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
180 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspensjoni għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 x (5 x 3ml) pinen mimlijin għal- lest.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
PREKAWZJONIJIET SPEĊJALI GĦAR- RIMI TA ’ PRODOTTI MEDIĊINALI MHUX
174 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
182 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix25 100 U/ ml KwikPen, suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Humalog Mix25 100 U/ ml KwikPen, suspensjoni għall- injezzjoni 25% insulina lispro and 75% insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
175 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
183 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog Mix50 100 U/ ml KwikPen, suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension (rDNA origin)
Humalog Mix50 100 U/ ml KwikPen, suspensjoni għall- injezzjoni 50% insulina lispro and 50% insulina lispro protamine suspensjoni (oriġini rDNA)
177 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
185 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspensjoni għall- injezzjoni, Parti minn pakkett multiplu ta ’ 2 X (5 X 3ml) pinen mimlijin għal- lest.
179 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
187 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog Mix50 100 U/ ml KwikPen, suspension for injection 50% insulin lispro and 50% insulin lispro protamine suspension Subcutaneous use
Humalog Mix50 100 U/ ml KwikPen, suspensjoni għall- injezzjoni 50% insulina lispro and 50% insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
180 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
188 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog BASAL 100 U/ ml KwikPen, suspension for injection Insulin lispro protamine suspension (rDNA origin)
Humalog BASAL 100 U/ ml KwikPeb, suspensjoni għall- injezzjoni Insulina lispro protamine suspensjoni (oriġini rDNA)
Suspension for injection 5 X 3ml pre-filled pens
Suspensjoni għall- injezzjoni, 5 x 3ml pinen mimlijin għal- lest.
182 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
190 TAGĦRIF LI GĦANDU JIDHER FUQ IL- PAKKETT TA ’ BARRA U L- PAKKETT LI JMISS MAL- PRODOTT
Humalog BASAL 100 U/ ml KwikPen, suspension for injection Insulin lispro protamine suspension (rDNA origin)
Humalog BASAL 100 U/ ml KwikPen, suspensjoni għall- injezzjoni Insulina lispro protamine suspensjoni (oriġini rDNA)
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspensjoni għall- injezzjoni, Parti minn pakkett multiplu 2 x (5 x 3ml) pinen mimlijin għal- lest.
184 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
192 TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL- PAKKETTI Ż- ŻGĦAR EWLENIN
Humalog BASAL 100 U/ ml KwikPen, suspension for injection Insulin lispro protamine suspension Subcutaneous use
Humalog BASAL 100 U/ ml KwikPen, suspensjoni għall- injezzjoni Insulina lispro protamine suspensjoni Għall- użu taħt il- ġilda
185 B.
193 B.
186 PACKAGE LEAFLET:
194 FULJETT TA ’ TAGĦRIF:
Humalog 100 U/ ml solution for injection in vial (insulin lispro)
Humalog 100 U/ ml, soluzzjoni għall- injezzjoni f’ kunjett (insulina lispro)
What Humalog is and what it is used for 2.
X’ inhu Humalog u għalxiex jintuża 2.
Before you use Humalog 3.
Qabel ma tuża Humalog 3.
How to use Humalog 4.
Kif għandek tuża Humalog 4.
How to store Humalog 6.
Kif taħżen Humalog 6.
WHAT HUMALOG IS AND WHAT IT IS USED FOR
X’ INHU HUMALOG U GĦALXIEX JINTUŻA
Humalog is used to treat diabetes.
Humalog huwa użat biex id- dijabete tiġi trattata.
Humalog works more quickly than normal human insulin because the insulin molecule has been changed slightly.
Taħdem aktar malajr minn insulina umana normali għax il- molekula ta 'l- insulina ġiet mibdula ftit.
You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood.
Ikollok id- dijabete jekk il- frixa tiegħek ma tagħmilx biżżejjed insulina biex tikkontrolla l- livell tal - glukożju fid- demm tiegħek.
Humalog is a substitute for your own insulin and is used to control glucose in the long term.
Humalog huwa sostitwent għall- insulina tiegħek u huwa użat biex jikkontrolla l- glukożju fuq medda twila ta ’ żmien.
It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours).
Jaħdem malajr ħafna u jdum għal anqas ħin mill - insulina li tinħall (2 sa 5 sigħat).
Your doctor may tell you to use Humalog as well as a longer-acting insulin.
It- tabib tiegħek jista 'jgħidlek biex tuża Humalog kif ukoll insulina li ddum taħdem għal ħin itwal.
Each kind of insulin comes with another patient information leaflet to tell you about it.
Kull tip t 'insulina tiġi ma' fuljett ta 'tagħrif ieħor għall- pazjenti biex jigħidlek fuqha.
Do not change your insulin unless your doctor tells you to.
Tbiddilx l - insulina tiegħek sakemm ma jgħidlekx it- tabib tiegħek.
Be very careful if you do change insulin.
Oqgħod attent ħafna jekk tibdel l- insulina tiegħek.
Humalog is suitable for use in adults and children.
Humalog huwa tajjeb għall- użu fl- adulti u fit- tfal.
Humalog may be used in children, when an advantage is expected compared to soluble insulin, for example, in the timing of the injection in relation to meals.
Humalog jista 'jintuża fit- tfal, meta vantaġġ huwa mistenni meta mqabbel ma' insulina li tinħall, per eżempju, it- teħid ta 'l- injezzjoni skond il- ħinijiet ta' l- ikliet.
BEFORE YOU USE HUMALOG
QABEL MA TUŻA HUMALOG
Do not use Humalog
Tużax HUMALOG
- if you think hypoglycaemia (low blood sugar) is starting.
- jekk taħseb li ġejja xi ipogliċemija (livell baxx ta ’ zokkor fid- demm).
Further in this leaflet it tells you
Iktar ’ il quddiem fil -
how to deal with mild hypoglycaemia.
fuljett se jkollok spjegat kif tista ’ tieħu kura ta ’ ipogliċemija ħafifa
- if you are allergic (hypersensitive) to insulin lispro or any of the other ingredients of Humalog.
Oqgħod attent ħafna b’ Humalog
Take special care with Humalog • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
195 • Jekk il- livelli taz- zokkor fid- demm tiegħek huma kkontrollati sew bit- terapija ta 'l- insulina li qed tuża bħalissa, tista' ma tħossx is- sintomi ta 'twissija meta jinżillek wisq iz- zokkor fid - demm.
Warning signs are listed later in this leaflet.
Sinjali ta 'twissija huma mniżżla aktar tard f' dan il- fuljett.
You must think carefully about when to have your meals, how often to exercise and how much to do.
Għandek taħseb sew dwar meta tiekol, kemm- il darba tagħmel eżerċizzju u kemm għandek tagħmel.
You must also keep a close watch on your blood sugar levels by testing your blood glucose often.
Għandek ukoll iżżomm osservazzjoni fuq il- livelli taz- zokkor tiegħek billi tittestja ta 'spiss il- glukożju fid - demm tiegħek.
187 • A few people who have had hypoglycaemia after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or different.
• Ftit nies li kellhom zokkor baxx fid- demm wara li qalbu minn insulina ta 'l- annimali għal isulina umana rrapportaw li l- ewwel sintomi ta' twissija kienu anqas ovji jew differenti.
If you often have hypoglycaemia or have difficulty recognising it, please discuss this with your doctor. • If you answer YES to any of the following questions, tell your doctor, pharmacist or diabetes nurse
Jekk spiss ikollok zokkor baxx fid- demm jew jekk għandek diffikultà biex tagħrafha, jekk jogħġbok iddiskuti dan mat- tabib tiegħek.
- - -
Jekk tirrispondi IVA għal xi mistoqsijiet li ġejjin, għid lit- tabib tiegħek, lill- ispiżjar jew lill- infermier tad- dijabete.
Have you recently become ill?
• Kont ma tiflaħx dan l- aħħar?
Do you have trouble with your kidneys or liver?
• Għandek xi problemi bil- kliewi jew bil- fwied?
Are you exercising more than usual?
• Qed tagħmel aktar eżerċizzju mis- soltu?
• The amount of insulin you need may also change if you drink alcohol. • You should also tell your doctor, pharmacist or diabetes nurse if you are planning to go abroad.
• Għandek ukoll tgħid lit- tabib tiegħek, lill- ispiżjar jew l- infermier tad- dijabete jekk qed tippjana biex issiefer.
The time difference between countries may mean that you have to have your injections and meals at different times from when you are at home.
Id- differenza fil- ħin bejn il- pajjiżi tista 'tfisser li jkollok tieħu l- injezzjonijiet u l - ikliet f' ħinijiet differenti milli meta tkun id- dar.
Using other medicines Your insulin needs may change if you are taking the contraceptive pill, steroids, thyroid hormone replacement therapy, oral hypoglycaemics, acetyl salicylic acid, sulpha antibiotics, octreotide, “ beta2 stimulants” (for example ritodrine, salbutamol or terbutaline), beta-blockers, or some antidepressants (monoamine oxidase inhibitors), danazol, some angiotensin converting (ACE) inhibitors (for example captopril, enalapril), and angiotensin II receptor blockers.
Meta tuża mediċini oħra Il- bżonnijiet tiegħek ta 'l- insulina jistgħu jinbidlu jekk qed tieħu il- pillola kontraċettiva, sterojdi, terapija biex tpatti għan- nuqqas ta' l- ormoni tat- tirojde, mediċini orali li jbaxxu z- zokkor fid- demm, acetyl salicylic acid, antibijotiċi sulpha, octreotide, "stimulanti tat- tip beta 2" (per eżempju ritodrine, salbutamol jew terbutaline), imblokkaturi tat- tip beta, jew ċerti antidipressanti (impedituri ta ’ monoamine oxidase), danazol, ċerti impedituri t' enżimi li jibdlu l- anġjotensina (per eżempju captopril, enalapril) u sustanzi li jibblukkjaw ir- riċetturi anġjotensin II
Please tell your doctor, if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Jekk jogħġbok għid lit- tabib jew lill- ispiżjar tiegħek jekk qiegħed tieħu jew ħadt dan l- aħħar xi mediċini oħra, anki dawk mingħajr riċetta.
Pregnancy and breast-feeding Are you pregnant or thinking about becoming pregnant, or are you breast-feeding?
Tqala u Treddigħ Inti tqila b' tarbija jew qed taħseb biex tinqabad tqila, jew qed tredda?
The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months.
L- ammont ta 'l- insulina li jkollok bżonn issoltu taqa' waqt l- ewwel tlett xhur tat- tqala u tiżdied għal l- aħħar sitt xhur.
If you are breast-feeding, you may need to alter your insulin intake or diet.
Jekk qed tredda, jista 'jkollok bżonn tibdel l- ammont ta ’ l- insulina li qed tieħu jew tibdel id- dieta.
Ask your doctor for advice.
Itlob il- parir tat- tabib jew ta ’ l- ispiżjar tiegħek qabel tieħu xi mediċina.
Driving and using machines Your ability to concentrate and react may be reduced if you have hypoglycaemia.
Sewqan u tħaddim ta ’ magni Il- ħila tiegħek biex tikkonċentra u tirreaġixxi tista 'tonqos jekk għandek zokkor baxx fid- demm.
Please keep this possible problem in mind in all situations where you might put yourself and others at risk (e. g. driving a car or operating machinery).
Jekk jogħġbok żomm din il- problema f' moħħok f' kull sitwazzjoni fejn tkun tista 'tpoġġi lilek innifsek jew oħrajn f' riskju (eż. sewqan ta' karozza jew tħaddim ta 'magni).
You should contact your doctor about the advisability of driving if you have: • frequent episodes of hypoglycaemia • reduced or absent warning signs of hypoglycaemia
Għandek tikkuntatja lit- tabib tiegħek dwar is- sewqan jekk għandek:
3.
196 3.
HOW TO USE HUMALOG
KIF GĦANDEK TUŻA HUMALOG
Always check the pack and the vial label for the name and type of the insulin when you get it from your pharmacy.
Dejjem eżamina il- pakkett u t- tabella tal- kunjett għall- isem u għat- tip ta 'l- insulina meta ġġibu mill- ispiżerija.
Make sure you get the Humalog that your doctor has told you to use.
Kun żgur li ġġib Humalog li t- tabib tiegħek qallek biex tuża.
Always use Humalog exactly as your doctor has told you.
Dejjem għandek tuża Humalog skond il- parir tat- tabib.
Dosage • You should normally inject Humalog within 15 minutes of a meal.
• Normalment għandek tinjetta Humalog fi żmien 15- il minuta qabel ikla.
If you need to, you can inject soon after a meal.
Jekk ikollok bżonn, tista 'tinjetta eżatt wara ikla.
But your doctor will have told you exactly how much to use, when to use it, and how often.
Imma t- tabib tiegħek ikun qallek eżatt kemm għandek tuża, meta għandek tużha, u kemm- il darba.
These instructions are only for you.
Dawn l- istruzzjonijiet huma għalik biss.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
• Jekk tibdel it- tip ta 'l- insulina li tuża (per eżempju minn insulina umana jew minn ta' l - annimali għall- prodott ta 'Humalog), jista' jkun ikollok bżonn tieħu aktar jew anqas minn qabel.
This might just be for the first injection or it may be a gradual change over several weeks or months. • Inject Humalog under the skin.
Dan jista 'jkun biss għal l- ewwel injezzjoni jew tista' tkun bidla gradwali tul ħafna ġimgħat jew xhur.
You should only inject it into a muscle if your doctor has told you to.
Għandek tinjetta f’ muskolu biss jekk hekk qallek it- tabib tiegħek.
188 Preparing Humalog • Humalog is already dissolved in water, so you do not need to mix it.
• Humalog huwa diġa maħlul fl- ilma, għalhekk m' għandekx bżonn tħalltu.
But you must use it only if it looks like water.
Imma għandek tużah biss jekk jidher qisu ilma.
It must be clear, have no colour and no solid pieces in it.
Għandu jkun trasparenti, bla kulur u bla biċċiet solidi ġo fih.
Check each time you inject yourself.
Eżamina dan kull darba li tinjetta ruħek.
Injecting Humalog • First wash your hands. • Before you make an injection, clean your skin as you have been instructed.
• Qabel ma tagħmel l- injezzjoni, naddaf il- ġilda tiegħek kif ġejt mgħallem.
Clean the rubber stopper on the vial, but do not remove the stopper. • Use a clean, sterile syringe and needle to pierce the rubber stopper and draw in the amount of Humalog you want.
Naddaf it- tapp tal - gomma fuq il- kunjett, imma tneħħix it- tapp.
Your doctor or clinic will tell you how to do this.
It- tabib tiegħek jew il- klinika jgħidulek kif għandek tagħmel dan.
Do not share your needles and syringes. • Inject under the skin, as you were taught.
• Injetta taħt il- ġilda, kif ġejt mgħallem.
After your injection, leave the needle in the skin for five seconds to make sure you have taken the whole dose.
Wara l- injezzjoni tiegħek, ħalli l- labra fil- ġilda għal ħames sekondi biex tkun żgur li ħadt id- doża kollha.
Do not rub the area you have just injected.
Torokx il- parti li għadek kif injettajt.
Make sure you inject at least half an inch (1 cm) from the last injection and that you ‘ rotate’ the places you inject, as you have been taught.
Kun żgur li tinjetta għal ta 'l- anqas nofs pulzier (1 cm)' l bogħod mill- aħħar injezzjoni u li tbiddel il- postijiet li tinjetta, kif ġejt mgħallem.
It doesn’ t matter which injection site you use, either upper arm, thigh, buttock or abdomen, your Humalog injection will still work quicker than soluble human insulin. • Your doctor will tell you if you have to mix Humalog with one of the human insulins.
Mhux importanti liema sit tuża, jew il- parti ta 'fuq tad- driegħ, il- koxxa, il- warrani jew fiż- żaqq, l- injezzjoni ta' Humalog xorta taħdem aktar malajr minn insulina umana li tinħall.
For example if you do need to inject a mixture, draw the Humalog into the syringe before the long acting insulin.
Per eżempju jekk għandek bżonn tinjetta taħlita, iġbed Humalog f' siringa qabel l- insulina li ddum taħdem għal ħin itwal.
Inject the liquid as soon as you have mixed it.
Injetta l- likwidu eżatt kif tkun ħallattu.
Do the same thing every time.
Għamel l- istess ħaġa kull darba.
You should not normally mix Humalog with one of the mixtures of human insulins.
Normalment m' għandekx tħallat Humalog ma 'waħda mit- taħlitiet ta' l- inulini umani.
You should never mix Humalog with insulins produced by other manufacturers or animal insulins. • You must not administer Humalog by the intravenous route.
M' għandek qatt tħallat Humalog ma 'insulini prodotti minn manifatturi oħra jew ma' insulini minn annimali.
Inject Humalog as your physician or nurse has taught you.
197 • M' għandekx tagħti Humalog ġol- vina.
Only your physician can administer Humalog by the intravenous route.
It- tabib tiegħek biss jista 'jagħti Humalog ġol- vina.
He will only do this under special circumstances such as surgery or if you are ill and your glucose levels are too high.
Huwa jagħmel hekk f' ċirkostanzi speċjali biss bħal kirurġija jew jekk ma tiflaħx u l- livelli tal- glukożju tiegħek huma wisq għolja.
Using Humalog in an infusion pump • Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro.
• Ċerti Minimed u Disetronic pompi ta 'l- infużjoni ta' l- insulina biss jistgħu jintużaw biex tkun tista 'tieħu l- infużjoni ta' l- insulina lispro.
Before infusing insulin lispro, the manufacturers instructions should be studied to ascertain the suitability or otherwise for the particular pump.
Qabel l- infużjoni ta 'l- insulina lispro, għandhom jkunu studjati l- istruzzjonijiet tal- manifatturi biex tkun żgur jekk dik il- pompa partikolari hijiex tajba jew le.
Read and follow the instructions in the product literature supplied with the infusion pump. • Be sure to use the correct reservoir and catheter for your pump. • Change the infusion set every 48 hours.
Uża metodi asettiċi meta iddaħħal is- sett ta 'l - infużjoni.
Use aseptic technique when inserting the infusion set. • In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved.
• Fil- każ t' episodju ta ’ zokkor baxx fid- demm, l- infużjoni għandha titwaqqaf sakemm jgħaddi l - episodju.
If repeated or severe low blood glucose levels occur, notify your doctor or clinic and consider the need to reduce or stop your insulin infusion. • A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels.
Jekk taħseb li hemm interruzzjoni fil- ħruġ ta 'l- insulina, segwi l- istruzzjonijiet fil- letteratura tal- prodott u jekk xieraq, għid lit- tabib tiegħek jew il - klinika.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic. • When used with an insulin infusion pump, Humalog should not be mixed with any other insulin.
• Meta użat b' pompa ta 'l- infużjoni ta' l- insulina, Humalog m' għandux jitħallat ma 'xi insulina oħra.
If you take more Humalog than you need If you take more Humalog than you need, a low blood sugar may occur.
Jekk tuża Humalog aktar milli suppost Jekk tuża Humalog aktar milli suppost, jista ’ jkollok livell baxx ta ’ zokkor fid- demm.
If your blood sugar is low, eat glucose tablets, sugar or drink a sugary drink.
Iċċekkja l- livell taz- zokkor fid- demm tiegħek. Jekk iz- zokkor fid- demm tiegħek huwa baxx, kul il- pilloli tal- glukożju, zokkor jew ixrob xarba ħelwa.
Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest.
Imbagħad kul il- frott, gallettini, jew sandwiċċ, kif qallek it- tabib tiegħek u strieħ ftit.
This will often get you over mild hypoglycaemia or a minor insulin overdose.
B' hekk ħafna mid- drabi jirnexxilek tirkupra minn effetti ta ’ ftit zokkor baxx fid - demm jew minn doża eċċessiva ħafifa ta ’ insulina.
If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once.
Jekk tmur għal agħar u qed tieħu nifs baxx u l - ġilda tiegħek tibjad, għid lit- tabib tiegħek minnufih.
A glucagon injection can treat quite severe hypoglycaemia.
Injezzjoni tal- glukagon tista 'tikkura zokkor baxx ħafna fid- demm.
Eat glucose or sugar after the glucagon injection.
Kul il- glukożju jew zokkor wara l- injezzjoni tal- glukagon.
If you do not respond to glucagon, you will have to go to hospital.
Jekk ma jgħaddilekx bil - glukagon, ikollok tmur l- isptar.